Eli Lilly and Company, a pharmaceutical company based in Indianapolis, Indiana, revealed it has teamed up with Amazon Pharmacy to help deliver its Zepbound weight loss drug and other medicines straight to customers' homes.
It struck a partnership deal with the online pharmacy subsidiary of Amazon Inc. just four months after obtaining the required regulatory approval to sell its diabetes treatment under a different name and category: weight loss.
Lilly's Weight Loss Treatment
According to CBS News, Eli Lilly's Tirzepatide drug, currently sold as a Mounjaro brand for diabetes, is now on the market under the new name Zepbound. It is also advertised as a weight-loss medication administered using an injection pen.
The company reportedly started selling Zepbound earlier this year. The drugs are directly sold to patients. Patients consult with doctors and obtain prescriptions from digital pharmacies, and the drugs are delivered to them.
Amazon Pharmacy Added as Home Delivery Option
Its partnership with Amazon's pharmacy unit allows patients and customers to obtain their medications quickly. In addition to Amazon Pharmacy, Eli Lilly delivers drugs to its customers via Truepill.
"Lilly has selected Amazon Pharmacy as a dispensing pharmacy option, allowing patients to receive fast, free delivery of medications and 24/7 access to clinical pharmacists," Dr. Vin Gupta, Amazon Pharmacy's chief medical officer, said in a press release. "To help patients being treated for diabetes, obesity, and migraine, Amazon Pharmacy is now offering home delivery of select medications through LillyDirect."
Dr. Gupta added, "Lilly has selected Amazon Pharmacy to serve as a third-party dispensing provider for LillyDirect Pharmacy Solutions, delivering prescribed Lilly medications directly to a patient's home."
Photo by: James Yarema/Unsplash


Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations
CVS Health Signals Strong 2026 Profit Outlook Amid Turnaround Progress
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S.
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform
SpaceX Reportedly Preparing Record-Breaking IPO Targeting $1.5 Trillion Valuation
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 



